Cite
MLA Citation
J Moellmann et al.. “The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis.” European heart journal, vol. 42, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100144499064.0x00003e